Log In
Print
BCIQ
Print
Print this Print this
 

TT-211

  Manage Alerts
Collapse Summary General Information
Company Benitec Biopharma Ltd.
DescriptionAdeno-associated virus (AAV)-based vector containing an expression construct with a short hairpin RNA (shRNA) directed against an undisclosed target
Molecular Target
Mechanism of Action 
Therapeutic ModalityGene therapy: Viral vector: Adenovirus
Latest Stage of DevelopmentPreclinical
Standard IndicationAge-related macular degeneration (AMD)
Indication DetailsTreat wet age-related macular degeneration (AMD)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1.5M

$1.5M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today